Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
April 27 2023 - 7:00AM
Business Wire
Exicure, Inc. (Nasdaq: XCUR), historically an early-stage
biotechnology company focused on developing nucleic acid therapies
targeting ribonucleic acid against validated targets, today
announced that, effective as of April 26, 2023, Jung-Sang (Michael)
Kim was appointed as Chief Executive Officer and Chief Financial
Officer of the Company and a Class II director of the Company’s
board of directors (the “Board”). Mr. Kim succeeds Dr. Matthias
Schroff, who yesterday stepped down as Chief Executive Officer and
a Class I member of the Board, and Mr. Elias D. Papadimas, who
yesterday stepped down as our Chief Financial Officer. Effective as
of April 26, 2023, the Board also approved the appointment of
Jiyoung Hwang as a Class I director of the Board. Additionally,
effective as April 26, 2023, Seung Soo Shin resigned as a Class II
director and chairman of the Board. Additional information about
today’s announcement, including biographical information about Mr.
Kim and Ms. Hwang, will be filed on a Form 8-K with the U.S.
Securities and Exchange Commission.
About Exicure
Exicure, Inc. has historically been an early-stage biotechnology
company focused on developing nucleic acid therapies targeting
ribonucleic acid against validated targets. Following its recent
restructuring and suspension of clinical and development
activities, the Company is exploring strategic alternatives to
maximize stockholder value, both with respect to its historical
biotechnology assets and more broadly. For further information, see
www.exicuretx.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements in this press release other than statements of
historical fact may be deemed forward looking including, but not
limited to, statements regarding: the Company's current business
plans and objectives, including the pursuit of strategic
alternatives to maximize stockholder value. Words such as “plans,”
“expects,” “will,” “anticipates,” “continue,” “advance,”
“believes,” “target,” “may,” “intend,” “could,” and other words and
terms of similar meaning and expression are intended to identify
forward-looking statements, although not all forward-looking
statements contain such terms. Forward-looking statements are based
on management’s current beliefs and assumptions that are subject to
risks and uncertainties and are not guarantees of future
performance. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause the Company’s
actual results to differ from those contained in the
forward-looking statements, see the section titled “Risk Factors”
in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2022 filed with the Securities and Exchange Commission
on March 27, 2023, as updated by the Company’s subsequent filings
with the Securities and Exchange Commission. All information in
this press release is as of the date of the release, and the
Company undertakes no duty to update this information or to
publicly announce the results of any revisions to any of such
statements to reflect future events or developments, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230427005349/en/
Media: Karen Sharma MacDougall 781-235-3060
ksharma@macdougall.bio
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024